Laurence Beck
Nephrology · Boston, MANPI 1912954371
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $22,620 of the $25,435 with a category attached, or 88.9%. 6 manufacturers reported payments, led by Travere Therapeutics, Inc. at 37.6% of the total. 2025 is the largest year on record at $7,970, more than ten times the $291 reported in 2019.
Across 34 payments — averaging $748.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$10K
- Otsuka Pharmaceutical Co., Ltd.$8K
- AstraZeneca$5K
- Novartis$3K
- Apellis Pharmaceuticals, Inc.$169
- Pfizer$86
Across 4 payments — averaging $6335.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$25K
What the payments were for
- Consulting fees$22,62089%
- Travel & lodging$1,1184%
- Food & beverage$1,5176%
- Education$1791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 22 | $9,556 |
| Otsuka Pharmaceutical Co., Ltd. | 4 | $8,080 |
| AstraZeneca | 3 | $4,925 |
| Novartis | 2 | $2,620 |
| Apellis Pharmaceuticals, Inc. | 2 | $169 |
| Pfizer | 1 | $86 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$25,435 in reported general payments places this provider in the 85th percentile of 339 nephrology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $5,959 |
| Torsemide | 71 | $1,598 |
| Spironolactone | 17 | $336 |
| Calcitriol | 25 | $304 |
| Carvedilol | 11 | $149 |
| Tamsulosin Hcl | 16 | $125 |
| Atorvastatin Calcium | 11 | $122 |
| Lisinopril | 17 | $120 |
| Amlodipine Besylate | 11 | $95 |
| Furosemide | 15 | $93 |
| Losartan Potassium | 11 | $76 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Boston
- David FriedmanBoston$19.8M
- Martin PollakBoston$19.8M
- Dennis AusielloBoston$4.6M
- Ajay SinghBoston$916K
- Leslie FangBoston$388K
- Jean FrancisBoston$244K
- Joseph BonventreBoston$175K
- Andrew AllegrettiBoston$139K
- Ravi ThadhaniBoston$115K
- Meghan SiseBoston$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.